Replies to post #110601 on Biotech Values

[DewDiligence]

Some IRB’s take a dim view of sham infusions.

I agree with your last statement; now that Gilenya is approved, new oral agents will presumably be tested head-to-head vs Gilinya, and new injectable agents can continue to be tested head-to-head vs any of several comparators.